

Design, Synthesis, Molecular Docking, and In Vitro Antibacterial Evaluation of Benzotriazole-Based β -Amino Alcohols and Their Corresponding 1,3-Oxazolidines

Naseeb Singh,^{*,†} Vidushi Abrol,[†] Sarita Parihar, Satish Kumar, Ghazala Khanum, Jan Mohammad Mir, Alamgir Ahimad Dar,^{*} Sundeep Jaglan, Mika Sillanpää, and Saleh Al-Farra

Cite This: ACS Omega 2023, 8, 41960–41968

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: In the present study, a series of benzotriazole-based β -amino alcohols were efficiently synthesized in excellent yields via aminolysis of benzotriazolate esters under catalyst- and solvent-free conditions. Further these β -amino alcohols were successfully utilized to synthesize the corresponding benzotriazole-based oxazolidine heterocyclic derivatives. All the synthesized compounds were characterized by various spectroscopic techniques such as ^1H NMR, ^{13}C NMR, and mass spectroscopy for structure elucidation. The compounds were subjected to a microtiter plate-based antimicrobial assay. The antimicrobial activity results reveal that the compounds **4a**, **4e**, and **5f** were found to be active against *Staphylococcus aureus* (ATCC-25923) with minimum inhibitory concentrations (MICs) of 32, 8, and 64 μM , respectively. Also, the compounds **4a**, **4e**, **4k**, **4l**, **4m**, **4n**, **4o**, **5d**, **5e**, **5f**, **5g**, and **5h** showed effective activity against *Bacillus subtilis* (ATCC 6633) with MICs of 64, 16, 16, 16, 64, 16, 64, 64, 32, 64, 8, and 16 μM , respectively. A biological investigation was conducted, including molecular docking of two compounds with several receptors to identify and confirm the best ligand–protein interactions. Hence, this study found a significant strategy to diversify the chemical molecules. The synthesized compounds play a potential role as an antibacterial intensifier against some pathogenic bacteria for the development of antibacterial substances.



1. INTRODUCTION

Azoles, particularly the benzotriazole nucleus has a key role in both heterocyclic chemistry and medicinal chemistry.^{1–3} Examples include the extensive use of benzotriazole-based compounds in the treatment of a wide range of diseases, including as anticarcinogenic,^{4,5} antibacterial and antifungal,^{6–8} and antimicrobial, antiparasitic, antiviral, antimycobacterial, and antitubulin agents.⁹ Furthermore, it should be noted that benzotriazole scaffolds have stacking interactions because of the conjugated benzene ring structure, which forms hydrogen bonds with a number of enzymes and receptors.⁹ For instance, alizapride⁸ and vorozole⁹ both include a benzotriazole moiety, and these formulations exhibit outstanding inhibitory effects against a variety of proteins (Figure 1). Additionally, benzotriazole esters have been demonstrated to be effective mechanism-based inactivators of the (SARS) 3CL protease.¹⁰

Because of their improved solubility due to effective hydrogen bonding with biomolecular targets, benzotriazole derivatives were found to have a wide range of biological activities, including antitubercular, antibacterial, antiallergic, anti-HIV, antifungal, antiviral, and anti-inflammatory properties.

In light of the aforementioned biological applications, the benzotriazole moiety has been frequently used to construct biologically potent molecules which not only imparts significant properties like hydrophilicity, lipophilicity, and minimal side effects but also enhances their bioactivities.^{11–18} Additionally, this will help to curb the drug-resistant pathogens, which will boost the prospects of developing superior drug alternatives.^{19,20} On the other hand, β -amino alcohols are an elite class of compounds that have a wide range of medicinal applications.^{21–25} Additionally, they were extensively used in the synthesis of unnatural amino acids^{26,27} as well as in asymmetric synthesis such as chiral ligands and auxiliaries.^{28,29} Therefore, it is anticipated that the




Figure 1. Benzotriazole moiety agonists.

Received: September 22, 2023

Revised: October 12, 2023

Accepted: October 17, 2023

Published: October 27, 2023




addition of a biologically active β -amino alcohol moiety to a benzotriazole scaffold will complement their action, perhaps improving the total pharmacological activity. It is important to note that screening of powerful and hybrid heterocycles has developed into a modern trend in biomedical development programs.^{24–29}

2. RESULTS AND DISCUSSION

2.1. Chemistry. **2.1.1. Synthesis of Benzotriazole-Based β -Amino Alcohol and Corresponding 1,3-Oxazolidines.** The title compounds benzotriazole-based β -amino alcohols and the corresponding 1,3-oxazolidines were manufactured by utilizing the retrosynthetic method shown in Scheme 1. The major

Scheme 1. Retrosynthetic Strategy for Benzotriazole Scaffolds




objective of this work was to improve benzotriazole chemistry^{30,31} in order to create various types of β -amino alcohol analogues with 1,2,3-benzotriazole as the main heterocyclic component (for antibacterial screening, etc.). There are few reports in the literature that demonstrates the antibacterial activity of β -amino alcohols.^{32–37} Therefore, to create medicinally advantageous antibacterial benzotriazole β -blocker analogues 4 and their equivalent oxazolidines 5, a well-planned retrosynthetic technique was used to introduce a powerful β -amino alcohol unit into the benzotriazole nucleus (Scheme 1).

The main components needed to achieve the target compounds are 1-hydroxybenzotriazoles 2a–f (HOBt) and benzotriazole epoxides 3a–f (Scheme 2). The new significant protocol is the result of our ongoing efforts to synthesize benzotriazole-based motifs as possible pharmacophores.^{38,39}

The fabricated HOBt 2a–f and associated benzotriazolated glycidyl ethers 3a–f served as starting materials for the synthetic methods (see the Experimental Section). Only a few reports on the synthesis of HOBt have been published in the literature,^{40–50} and most of these are associated with one or more limitations, such as a long reaction time, a low yield, and vigorous reaction conditions. As a result, it was thought to be beneficial to devise a rapid and efficient procedure for producing HOBt from easily available raw materials for the synthesis of target compounds (Scheme 2, step a). We used the microwave (MW) irradiation condition as a nonconventional energy source to rapidly accomplish our goal. In this instance, MW reactor radiation was applied to an equimolar mixture of appropriate 2-nitrochlorobenzene and hydrazine hydrate in the presence of alcoholic sodium carbonate (Biotage, model: Initiator EXP EU 355301, 012180). Only

Scheme 2. Preparation of Benzotriazole-Based β -Amino Alcohol and Corresponding 1,3-Oxazolidines^a




^a(a) Alcoholic Na_2CO_3 , MW, 70/120 $^\circ\text{C}$, 10/25 min; (b) (i) DMSO/ K_2CO_3 (1 equiv), rt, (ii) (+)-epichlorohydrin, rt, 2–3 h, 80–90%; (c) neat, rt, few drops of dichloromethane in case both reactants are solids; (d) $(\text{CH}_3\text{O})_2$, neat grinding, rt.

10–25 min was required for the formation of products 2a–f in an excellent yield of 80–90%.


The required benzotriazole-based glycidyl ethers 3a–f were then produced in high percentage yields of 80–90% within 2–3 h via reactions between 2a–f and (+)-epichlorohydrin at room temperature (Scheme 2 step b). The products 3a–f were extracted by using chloroform, which were then purified by using flash chromatography with an ethyl acetate and *n*-hexane system and examined through spectral techniques such as ^1H nuclear magnetic resonance (NMR), ^{13}C NMR, and mass spectrometry (MS). Then, utilizing the optimal conditions stated in Scheme 2 (step c), benzotriazole-based glycidyl ethers 3a–f were exposed to aminolysis to create a novel series of benzotriazole-based β -amino alcohols. Although there are a number of approaches for the regioselective synthesis of β -amino alcohols by opening the rings of epoxides,^{52,53} the approach that uses aqueous conditions and catalyst-free conditions has caught our attention, particularly in light of green chemistry principles.^{54–57} As a result, we planned to carry out aminolysis of 3a using isopropylamine under aqueous conditions. As anticipated, an obvious reaction took place within 1 h, producing the necessary product 4m with an excellent yield (90%). The reaction was also performed in other polar solvents, such as CH_3CN (acetonitrile), tetrahydrofuran, CCl_4 (carbon tetrachloride), and DCM (dichloromethane); however, water turned out to be most effective of the examined solvents. Interestingly, the reaction was investigated under neat conditions to produce the highest yield of the target chemical 4m (Table 1, entry 9), indicating that catalyst- and solvent-free conditions were the most favorable for the anticipated reaction. However, in situations where both reactants are in the solid state, just a few drops of dichloromethane were added to homogenize the reaction contents.

The process was then applied to various benzotriazole glycidyl ethers 3b–f containing fluoro, chloro, methoxy, and nitro groups. The reaction outcome is summarized in Table 2. The synthetic benzotriazole glycidyl ethers 3 have presumably demonstrated more reactivity than regularly used and available epoxides (such as styrene epoxide, cyclohexene epoxide, and cyclopentene epoxide). It is significant to note that regioselectivity was also observed similar to the previous report.⁵⁸ Fourteen newer product molecules 4a–p were generated without using a catalyst under neat reaction conditions, as indicated in Table 3.

Table 1. Optimization of Reaction Conditions^a


entry	solvent	time (min) ^b	yield (%) ^c
1	CH ₃ CN	120	84
2	CHCl ₃	60	83
3	CH ₂ Cl ₂	60	82
4	toluene	180	89
5	DMF	120	73
6	DMSO	150	72
7	water	60	90
8	benzoin	60	65
9	neat	25	95

^aStirring at room temperature. ^bTime required for completion of the reaction. ^cYield of the isolated and purified product 4a.

Table 2. Optimization of Reaction Conditions^a


entry	catalyst (mol %/mg)	solvent	time (h/min) ^b	% yield (2a) ^c
1	catalyst (0)	formaldehyde ^d	24 h	20
2	NaOH (10)	formaldehyde	24 h	40
3	NaOH (10)	EtOH ^e	10 h	90
4	NaOH (10)	MeOH	10 h	85
5	NaOH (10)	neat	05 min	98
6	catalyst (0)	neat	15 min	30
7	NaOH (5)	neat	05 min	80
8	NaOH (15)	neat	05 min	98
9	KOH (10)	neat	05 min	97
10	LiClO ₄ (10)	neat	10 min	70
11	K ₂ CO ₃ (10)	neat	10 min	68
12	NaHCO ₃ (10)	neat	15 min	65
13	Na ₂ CO ₃ (10)	neat	10 min	69
14	barium alumina (50 mg)	neat	15 min	66

^a1,2-Amino alcohol 4a (0.5 mmol), paraformaldehyde (200 mg), and Na₂CO₃ (100 mg) were used. ^bTime taken for completion of the reaction (TLC). ^cIsolated yield of the purified product 5a. ^d37–41% solution of formaldehyde in water was used (formalin). ^e2 mL of super dry alcohol (EtOH and MeOH) was used under reflux conditions.

Additionally, it has been confirmed through spectroscopy that exclusive formation of β -amino alcohols with a secondary alcohol functionality was observed in the present investigation. The formation of single regiomers has also been supported by the theoretical studies (see Supporting Information).

A series of matching benzotriazole-based 1,3-oxazolidines 5a–j were produced in excellent yield by cyclizing the synthesized β -amino alcohol molecules utilizing paraformaldehyde in the presence of 10 mol % alkali, as shown in Table 3.³⁹

As these scaffolds are known to exhibit a wider range of bioactivities,^{38–45} we then carried out the synthesis of certain benzotriazole-based 1,3-oxazolidines as medicinally privileged pharmacophores that may operate as a potential therapeutic

molecule (Scheme 2, step d). The formation of target molecules, i.e., benzotriazole-based β -amino alcohols 4a–p and benzotriazole-based 1,3-oxazolidines 5a–j, were satisfactorily confirmed through ¹H NMR, ¹³C NMR, and MS techniques.^{33,39}

2.2. Antimicrobial Activity of Compounds. The 96-well microtiter plate assay results reveal that the compounds 4a, 4e, and 5f were found active against *Staphylococcus aureus* [American Type Culture Collection (ATCC) 25923] with minimum inhibitory concentrations (MICs) of 32, 8, and 64 μ M, respectively. Also, the compounds 4a, 4e, 4f, 4i, 4m, 4n, 4o, 5d, 5e, 5f, 5g, and 5h showed effective activity against *Bacillus subtilis* (ATCC 6633) with MICs of 64, 16, 16, 16, 64, 16, 64, 64, 32, 64, 8, and 16 μ M, respectively.

2.3. Biological Screening (Antimicrobial Screening of Compounds). The compounds were evaluated for their antimicrobial activity using the microdilution-based method [as per Clinical and Standards Institute (CLSI) guidelines] against two Gram-positive bacterial strains (*S. aureus* ATCC 25923 and *B. subtilis* ATCC 6633), two Gram-negative bacterial strains (*Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853), one yeast (*Candida albicans* ATCC 24433) and one filamentous fungi (*Aspergillus niger* ATCC 16404). The microdilution assays were performed in accordance with the procedures outlined by the CLSI. Mueller–Hinton agar (MHA) and Mueller–Hinton broth (MHB) were prepared as per the manufacturer's instructions (HiMedia Laboratories, India) for the antibacterial assay, and for antifungal testing Sabouraud dextrose broth (SDH) was used. The precultures of the strains were prepared in MHB and SDH by fresh inoculum of the cultures incubated at 37 °C for 18–24 h (for bacteria) and at 28 °C for 48 h for the fungal cultures with 100 rpm shaking to obtain concentrations of approximately 5–6 log CFU/mL (evaluated and adjusted spectrophotometrically at 625 nm). The bacterial suspensions were further diluted with MHB to obtain a final inoculum of 5×10^5 CFU/mL, and for fungal suspension 1×10^5 CFU/mL inoculum was used in SDH. The antibacterial assays were performed in clear 96-well U-bottom microtiter plates. Initially, the test compounds were screened for antibacterial activity at a slightly higher concentration (128 μ g/mL), and those that show inhibition in primary screening were further tested at different concentrations to obtain MIC and minimum bactericidal concentration (MBC) values. Each experiment was accompanied by a positive control containing broth, pathogen, and a known inhibitory compound amphotericin B or ciprofloxacin [16–0.03 μ g/mL], i.e., standard antifungal and antibacterial agents, respectively, and a negative control containing broth and pathogen. The plates were incubated for 24 h at 37 °C for bacterial cultures and at 28 °C for 48 h for fungal cultures, and then observations were recorded visually. The well containing a minimum concentration of the compound in which there is no visual growth is considered as MIC. A loopful inoculum from the wells containing no visual growth was streaked on the MHA/SDH plate for MBC/MFC (minimum fungicidal concentration).

2.4. Molecular Docking. Molecular docking studies help medicinal chemists to identify novel drugs at low cost and in a short amount of time. AutoDock Vina and Chimera software^{46,47} were used to efficiently achieve molecular docking. The docking approach was used to discover the optimum match of ligands and proteins with the least amount of energy. The compound 4e was docked with 6GLA protein

Table 3. Substrate Scope for the Synthesis of 4 and 5 under Optimized Conditions^a

 4a Yield: 92% (10 min)	 4b Yield: 94% (10 min)	 4c Yield: 95% (10 min)
 4d Yield: 95% (15 min)	 4e Yield: 94% (15 min)	 4f Yield: 94% (30 min)
 4g Yield: 95% (15 min)	 4h Yield: 93% (10 min)	 4i Yield: 94% (10 min)
 4j Yield: 93% (25 min)	 4k Yield: 93% (30 min)	 4l Yield: 92% (25 min)
 4m Yield: 95% (15 min)	 4n Yield: 96% (25 min)	 4o Yield: 95% (10 min)
 4p Yield: 95% (15 min)	 4q Yield: 98% (5 min)	 4r Yield: 98% (5 min)
 4s Yield: 96% (15 min)	 4t Yield: 96% (10 min)	 4u Yield: 96% (10 min)
 4v Yield: 95% (10 min)	 4w Yield: 97% (5 min)	 4x Yield: 97% (10 min)
 4y Yield: 96% (10 min)	 4z Yield: 98% (5 min)	

^aAll compounds gave satisfactory spectral (¹H NMR, ¹³C NMR, and ESI-MS) data and C, H, and N analysis within ±0.4%.

by using AutoDock software. The ligand was docked into the functional sites of the relevant protein one at a time, with the docking energy analyzed to find the lowest value. Figure 2 shows that 4e is involved in the π -sigma interaction with Leu956, many alkyl, as well as π -alkyl interactions with Tyr904, Val836, Ala966, Met902, Val884, and Ala853.

However, compound 4e also binds firmly to the active site through one conventional hydrogen bond (Leu828). While Pro906 formed a halogen (Cl) interaction, besides other residues also found to be bound to control drugs through van der Waals interaction depicted in a two-dimensional (2D) plot (Figure 2). Compound 5f binds through one conventional



Figure 2. 2D docking image of 4e docked into the binding site of 6GLA.

hydrogen bond (Arg485) and three π -alkyl interactions with Leu398, Arg488, besides these, one π - π T-shaped with Phe386, other interactions are also found to bound through carbon-hydrogen bonding and van der Waals interaction depicted in a 2D plot (Figure 3). The binding affinity energies of the control drugs are mentioned in Table 4.



Figure 3. 2D docking image of 5f docked into the binding site of 4WTB.

Table 4. Binding Affinity Energy of Control Drugs

compound	protein (ID)	bond distance (Å)	inhibition constant (micromolar)	binding energy (kcal/mol)
4e	6GLA	2.116, 2.519	1.876	-7.8
5f	4WTB	2.267, 2.372, 2.517	0.680	-8.4

If we compare the binding affinity energy of control drugs, compounds 4e and 5f have the highest negative binding energy with -7.8 and -8.4 kcal/mol, respectively.

2.5. HOMO–LUMO analysis. The highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) can be easily observed by using the GaussView program⁴⁸ and are given in Figure 4. The Frontier molecular orbitals make it possible to understand the local reactivity of molecules. According to Fukui,⁴⁹ to study a chemical reaction, only the two molecular orbitals HOMO and LUMO are of real interest. The HOMO provides information on the electron-donor character (nucleophilic site), whereas the LUMO indicates the electron-receptor character of the molecule (electrophilic site). The green color corresponds to the negative phase, and the red color indicates the positive phase. It can be seen from the plot of HOMO level of compound 5f, all positive and negative regions are spread over the six-membered ring attached with the methyl group and partially over the five-membered rings. In the LUMO level of




Figure 4. HOMO–LUMO with an energy gap.

compound 5f, positive and negative regions are distributed over the six-membered ring attached with a chlorine atom. Whereas in the HOMO of compound 4e, the positive and negative regions are spread over the phenyl ring and in the LUMO of compound 4e, the positive and negative regions are spread on the phenyl ring as well as on five-membered rings. The difference between the energy of the HOMO and LUMO is defined as the energy gap ΔE . This reflects the polarizability and chemical activity within a molecule. It promotes the transfer of charges in the molecule. This energy quantity allows characterizing the chemical reactivity and the kinetic stability of the molecule. When the HOMO–LUMO energy gap is high, the flow of electrons at the higher energy state is difficult, making the molecule hard and less reactive. Results reveal that the HOMO–LUMO energy gap ($E_{\text{HOMO}} - E_{\text{LUMO}}$) is equal to 3.60 eV in 5f and 3.84 eV in 4e, respectively.

3. EXPERIMENTAL SECTION

3.1. Materials and Methods. *o*-Nitrochlorobenzenes, hydrazine monohydrate hydrate (98%), substituted anilines, ($\pm$) epichlorohydrin (Sigma-Aldrich), sodium carbonate, potassium carbonate, aliphatic amines such as tertiary butylamine (HiMedia), and isopropyl amine (SDFCL) were used as received. Melting points were recorded in open capillaries using the ANALAB melting point apparatus. ¹H NMR (400 MHz) and ¹³C NMR (101/126 MHz) spectra were recorded in CDCl₃/CD₃OD solutions with TMS as the internal standard on a Bruker AVANCE III HD spectrometer. Mass analysis was carried out using Nexera UHPLC (at 130 MPa) with a SIL-30AC Nexera autosampler coupled to a liquid chromatography–mass spectrometry (LC–MS) 8030 tandem mass spectrometer manufactured by Shimadzu Corporation, Tokyo, Japan. The analysis of all these compounds was performed in a full scan mode with nitrogen as the interface gas.

3.2. Microbial Strains. Bacterial strains *S. aureus* ATCC 25923, *B. subtilis* ATCC 6633, *E. coli* ATCC 25922, and *P. aeruginosa* ATCC 27853; the yeast *C. albicans* ATCC 24433; and the fungal strain *A. niger* ATCC 16404 used for antimicrobial activity screening were procured from ATCC. The strains were cultured in potato dextrose broth (PDB) and nutrient agar at 28 and 37 °C, respectively, in Petri dishes for 3–5 days.

3.3. General Procedure for Synthesis of HOBt (2a–f). A mixture of *o*-nitro chlorobenzenes 1 (3 mmol) and hydrazine hydrate (9 mmol) in 5 mL of ethanol in the

presence of powdered Na_2CO_3 (3 mmol) was subjected to irradiation at the temperature of 70 °C in a MW reactor (Biotage, model: Initiator EXP EU 355301, 012180) for 10 min (except for 2f in which *n*-heptanol was used as the solvent and the MW vial was subjected to irradiation at 120 °C for 20–25 min). When the reaction got completed [according to thin-layer chromatography (TLC)], the mixture was poured in 20 mL of ice-cold water and its acidification was carried using 1 M HCl (pH, 3.2–3.5) to produce the crude product in the form of a white precipitate (2c was collected as a yellow precipitate). The precipitates were then subjected to filtration, washed using 5% NaCl (aqueous solution), and were subsequently subjected to purification by means of recrystallization either by utilizing EtOH or CHCl_3 /MeOH solvent system to produce products devoid of impurities in a very high yield (80–90%).

3.4. General Procedure for Synthesis of Derivatives of 1-(Oxirane-2-ylmethoxy)-1H-benzotriazole (3a–f). A mixture of 1-hydroxy benzotriazoles 2 (3 mmol) and ($\pm$)-epichlorohydrin (3.5 mmol) in 3 mL of dimethyl sulfoxide (DMSO) in the presence of powdered K_2CO_3 (3 mmol, activated at 40 °C) was stirred at room temperature for a duration of 2–3 h. Ten milliliters of distilled water was then added to the reaction mixture, and the product was extracted using chloroform (3 $\times$ 10 mL). The combined organic layers were washed using saturated NaHCO_3 aq. solution (2 $\times$ 3 mL), followed by distilled water (3 $\times$ 5 mL), then rinsed with 2 mL brine, and finally dried over anhydrous Na_2SO_4 . Removal of excess solvent was carried out under reduced pressure conditions, and the product obtained in a crude form was subjected to purification using column chromatography to obtain respective benzotriazole glycidyl ethers 3a–f in a high yield (80–90%).

3.5. General Procedure for Synthesis of Benzotriazole-Based β -Amino Alcohols (4a–p). A mixture of 3 (1 mmol) and an appropriate aromatic amine (1 mmol) was stirred at room temperature under solvent-free conditions. After completion of the reaction, as indicated by TLC, the product was purified by flash column chromatography using ethyl acetate/hexane as the solvent system. However, in the case of compounds 4g–j and 4l–n where an excess of isopropyl/tertiary butyl amine (2.5 mmol) was used, it was removed under reduced pressure before further purification. The structure of products 4 was confirmed by their elemental and spectral data.³⁸

3.6. General Procedure for Synthesis of Benzotriazole-Containing 1,3-Oxazolidines from β -Blockers (5a–j). A mixture of β -amino alcohol (0.5 mmol) and paraformaldehyde (200 mg) in the presence of 10 mol % NaOH and sodium sulfate (100 mg) were ground for 5–10 min using a mortar and pestle.³⁹ Reaction progress was checked through the traditional TLC method using *n*-hexane/EtOAc (1:1) as the solvent system until completion (TLC, Table 3). Afterward, 2–3 mL of DCM or chloroform was added, and the resulting product was purified through filtration. The residue on the filter paper was subsequently washed with additional 2–3 mL of the solvent. In the end, the so-collected filtrate was reduced under vacuum evaporation. The crude products so obtained were purified by chromatography utilizing 60–120 mesh size silica gel to get pure 1,3-oxazolidines 5a–j in an excellent yield.

4. CONCLUSIONS

The envisaged methodology has the advantage of opening the epoxide ring without any catalyst and solvent to afford the target molecule in an excellent yield (Table 3). In conclusion, a revised and efficient protocol advocating a catalyst- and solvent-free route is demonstrated toward the synthesis of diverse benzotriazole-based β -amino alcohols 4a–p in good to excellent yield. Subsequently, these β -amino alcohols were utilized to furnish the corresponding oxazolidines 5a–j. The structure of these compounds was thoroughly analyzed by ^1H NMR, ^{13}C NMR, and MS. All of the synthesized compounds were screened for *in vitro* pharmacological activities. It was observed that the compounds 4a, 4e, and 5f showed high potential antibacterial activity against *S. aureus* (ATCC 25923), while the compounds 4a, 4e, 4k, 4l, 4m, 4n, 4o, 5d, 5e, 5f, 5g, and 5h reveal potent activity against *B. subtilis* (ATCC 6633) and induced postantibiotic effects against both Gram-positive pathogens (Supporting Information). Molecular docking studies of compounds 4e and 4f were carried out on the proteins 6GLA and 4WH9. The resultant binding energy was -7.8 and -8.4 kcal/mol, indicating that the title compounds can be studied further for their medicinal application.

Our aim was to explore the bioactive antibacterial potential of the compounds that are synthesized through a novel methodology. It can be inferred that 4e, 4k, 4l, 4n, 5g, and 5h may act as potential chemical entities for the development of antibacterial substances. The molecular docking study confirms that these compounds are most suitable for further studies toward the development of antibacterial substances. Literature also has reported that these molecules show positive antibacterial activity.^{23–27} Therefore, here, through successful chemical modification and synthesis of the corresponding molecule with a high yield, we tried to evaluate the bioactive properties of the aforementioned molecules, and the results revealed that these chemical molecules successfully enhanced their antibacterial properties (pictures are presented in the Supporting Information). It is anticipated that silent metabolic pathways might have been involved, which become active after the successful synthesis of the chemical molecules. Hence, further efforts should be made, and further research should be conducted utilizing *in vivo* models to determine their efficacy as antibiotics.

Additionally, it is pertinent to mention that the present investigation is a result of our continuous efforts toward the development of greener methodologies for the creation of targeted bioactive heterocyclic scaffolds,^{38,47,50–54} quantification, and isolation cum purification techniques for biologically active components obtained from different sources.^{73–75}

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.3c07315>.

^1H NMR, ^{13}C NMR, and MS data and spectra; molecular docking study; biological activity images; HOMO–LUMO structures; and DFT study (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Naseeb Singh – Synthetic Organic Chemistry Laboratory, School of Biotechnology, Faculty of Sciences, Shri Mata

Vaishna Devi University, Jammu & Kashmir 182320, India; Department of Chemistry, Govt. Degree College Udhampur, Jammu and Kashmir 182101, India; naseehungamvdu@gmail.com; ORCID: 0000-0003-4159-8005; Phone: +91-9596697381, +91-8360169550; Email: naseehungamvdu@gmail.com
 Alamgir Ahmad Dar – Research Centre for Residue and Quality Analysis, Sher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST-K), Jammu & Kashmir 190025, India; Email: alamgirdar@skuastkashmir.ac.in

Authors

Vidushi Abrol – Fermentation & Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine Canal Road, Jammu, Jammu & Kashmir 180001, India; naseehungamvdu@gmail.com; ORCID: 0000-0002-8607-0282
 Sarita Parihar – Department of Physics, Govt. Degree College Udhampur, Jammu and Kashmir 182101, India
 Satish Kumar – Department of Chemistry, Govt. Degree College Udhampur, Jammu and Kashmir 182101, India
 Ghazala Khanum – Department of Chemistry, Govt. Degree College Udhampur, Jammu and Kashmir 182101, India
 Jan Mohammad Mir – Department of Chemistry, Islamic University of Science and Technology (IUST) Awantipora, Pulwama, J&K 192301, India
 Sundeep Jaglan – Fermentation & Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine Canal Road, Jammu, Jammu & Kashmir 180001, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh 201002, India; naseehungamvdu@gmail.com; ORCID: 0000-0002-5691-7980
 Mika Silampää – Department of Biological and Chemical Engineering, Aarhus University, Aarhus 8000, Denmark; Department of Chemical Engineering, School of Mining, Metallurgy and Chemical Engineering, University of Johannesburg, Doornfontein 2028, South Africa
 Saleh Al-Farraj – Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acsomega.3c07315>

Author Contributions

[†]NS and V.A. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors sincerely thank SMVDU Katra, University of Jammu, CSIR-IIIM Jammu, GNDU Amritsar, IIT Madras, and IUST Awantipora for providing facilities, spectral, and microanalysis data. This work was supported by the Researchers Supporting Project Number RSP-2024/17, King Saud University, Riyadh, Saudi Arabia.

ADDITIONAL NOTE

^aCaution: Preliminary mixing of corresponding *p*-nitro chlorobenzenes and hydrazine hydrate in a MW vial should be performed under ice-cold conditions and continuous stirring (exothermic reaction). Subsequent to this, the vial may be subjected to MW irradiation.

REFERENCES

- (1) Bajaj, K.; Sakhuja, R. Benzotriazole: Much More Than Just Synthetic Heterocyclic Chemistry. In *The Chemistry of Benzotriazole Derivatives*; Springer, 2015; pp 235–283.
- (2) Hall, C. D.; Panda, S. S. The Benzotriazole Story. In *Advances in Heterocyclic Chemistry*; Elsevier, 2016; Vol. 119, pp 1–23.
- (3) Brigaglia, L.; Piras, S.; Corina, P.; Gavini, E.; Nioeddi, M.; Bontis, G.; Carta, A. Benzotriazole: An overview on its versatile biological behavior. *Eur. J. Med. Chem.* 2015, 97, 612–648.
- (4) Bleiberg, H.; Gerold, R.; Dalein, O.; Crespignier, N.; Ravenswong, M. Activity of a new antiemetic agent, alizapride. *Cancer Chemother. Pharmacol.* 1998, 22, 316–320.
- (5) Goss, P. L. Pre-clinical and clinical review of vorinostat, a new third generation histone deacetylase inhibitor. *Breast Cancer Res. Treat.* 1998, 49, 559–566.
- (6) Gokul, N. D.; Patil, S. V.; Bhat, V. D. Synthesis and biological evaluation of some novel thiazole substituted benzotriazole derivatives. *Bioorg. Med. Chem. Lett.* 2012, 22, 3449–3454.
- (7) Shah, J. J.; Khoshkar, V.; Coutinho, E. C.; Mohanraj, K. Design, synthesis and evaluation of benzotriazole derivatives as novel antifungal agents. *Bioorg. Med. Chem. Lett.* 2015, 25, 3720–3727.
- (8) Ramachandran, R.; Rani, M.; Senthil, S.; Jeong, Y. T.; Kabilan, S. Synthesis, spectral, crystal structure and in vitro antimicrobial evaluation of imidazole/benzotriazole substituted piperidin-4-one derivatives. *Eur. J. Med. Chem.* 2011, 46, 1926–1934.
- (9) Singh, G.; Kumar, R.; Sweet, J.; Zajc, B. Modular synthesis of N-vinyl benzotriazoles. *Org. Lett.* 2013, 15, 4086–4089.
- (10) Wu, C.-Y.; King, K.-Y.; Kuo, C.-J.; Fang, J.-M.; Wu, Y.-T.; Ho, M.-Y.; Liao, C.-L.; Shie, J.-J.; Liang, P.-H.; Wong, C.-H. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease. *Chem. Biol.* 2006, 13, 261–268.
- (11) Ren, Y.; Zhang, L.; Zhou, C.-H.; Geng, R.-X. Recent development of benzotriazole-based medicinal drugs. *Med. Chem.* 2014, 4, 640–662.
- (12) Sarna, R.; Natesh, N.; Madhavan, V. Benzotriazole in medicinal chemistry: an overview. *J. Chem. Pharm. Res.* 2011, 3, 375–381.
- (13) Singh, V.; Rishabhwar, P.; Bhardwaj, P.; Alok, S. Benzotriazole: a heterocyclic molecule with diversified pharmacological activities. *Int. J. Pharm. Sci. Res.* 2017, 8, 446–456.
- (14) Peng, X.-M.; Cai, G.-X.; Zhou, C.-H. Recent developments in azide compounds as antibacterial and antifungal agents. *Curr. Top. Med. Chem.* 2013, 13, 1963–2010.
- (15) Fair, R. J.; Tse, Y. Antibiotics and bacterial resistance in the 21st century. *Perspect. Med. Chem.* 2014, 6, PMC514459.
- (16) Fung, I. W.; Shlaes, D.; Orlin, K. *Antimicrobial Resistance in the 21st Century*; Springer, 2018.
- (17) Cheng, B. L.; Ganesan, A. Solution-phase synthesis of a β -amino alcohol combinatorial library. *Bioorg. Med. Chem. Lett.* 1997, 7, 1511–1514.
- (18) Rogers, G. A.; Parotta, S. M.; Anderson, D.; Nilsson, I. M.; Babz, B. A.; Komruch, W. D.; Kaufman, R.; Jacobs, R. S.; Kirtman, B. Synthesis, in vitro acetylcholinesterase-inhibiting activities, and biological properties of derivatives and analogs of trim-2-(4-phenylpiperidino) cyclohexanol (vesamicol). *J. Med. Chem.* 1989, 32, 1217–1230.
- (19) De Créé, J.; Geukens, H.; Leempoels, J.; Verhaegen, H. Haemodynamic effects in man during exterior of a single oral dose of nifedipine (R 67555), a new β -1-adrenoceptor blocking agent: A comparative study with atenolol, pindolol, and propranolol. *Drug Dev. Res.* 1986, 8, 109–117.
- (20) O'Brien, P. Sharpless asymmetric aminohydroxylation: scope, limitations, and use in synthesis. *Angew. Chem. Int. Ed.* 1999, 38, 326–329.
- (21) Li, G.; Chang, H. T.; Sharpless, K. B. Catalytic asymmetric aminohydroxylation (AA) of olefins. *Angew. Chem. Int. Ed. Engl.* 1996, 35, 451–454.

- (22) Ager, D. J.; Prakash, I.; Schaud, D. R. 1, 2-Amino alcohols and their heterocyclic derivatives as chiral auxiliaries in asymmetric synthesis. *Chem. Rev.* 1996, 96, 835–876.
- (23) Bergmeier, S. C. The synthesis of vicinal amino alcohols. *Tetrahedron* 2000, 56, 2561–2576.
- (24) Kaur, R.; Palta, K.; Kumar, M.; Bhargava, M.; Dahiya, I. Therapeutic potential of oxazole scaffold: a patent review (2006–2017). *Expert Opin. Ther. Pat.* 2018, 28, 783–812.
- (25) Desai, N.; Trivedi, A.; Pandit, U.; Dodiya, A.; Kamnawara Rao, V.; Desai, P. Hybrid bioactive heterocycles as potential antimicrobial agents: a review. *Mini Rev. Med. Chem.* 2016, 16, 1503–1526.
- (26) Ahmad, K.; Khan, M. K. A.; Haig, M. H.; Iqbal, M.; Gupta, G. K. Role of azoles in cancer prevention and treatment: present and future perspectives. *Anti-Cancer Agents Med. Chem.* 2018, 18, 46–56.
- (27) Zhang, H.-Z.; Gan, L.-L.; Wang, H.; Zhou, C.-H. New progress in azole compounds as antimicrobial agents. *Mini Rev. Med. Chem.* 2016, 17, 122–166.
- (28) Zhang, H.-Z.; Zhao, Z.-L.; Zhou, C.-H. Recent advance inazole-based medicinal chemistry. *Eur. J. Med. Chem.* 2018, 144, 444–492.
- (29) Fan, Y.-L.; Jin, X.-H.; Huang, Z.-P.; Yu, H.-F.; Zeng, Z.-G.; Gao, T.; Feng, L.-S. Recent advances of imidazole-containing derivatives as anti-tubercular agents. *Eur. J. Med. Chem.* 2018, 150, 347–365.
- (30) Marchal, J.-C. M. *The Chemistry of Benzotriazole Derivatives*; Springer, 2016.
- (31) Ahmar, B.; Ballessteros-García, B. 1,2,3-Triazoles Fused to Aromatic Rings. In *Chemistry of 1, 2, 3-triazoles*; Springer, 2014; pp 325–378.
- (32) Rao, K. G.; Arun, Y.; Eswarananth, K.; Balachandran, C.; Prakash, T.; Venkaj, T. E.; Perumal, P. T. Synthesis, antimicrobial and molecular docking studies of enantiomerically pure *N*-alkylated β -amino alcohols from phenylpropanolamines. *Bioorg. Med. Chem. Lett.* 2014, 24, 3057–3063.
- (33) Yendapally, R.; Lee, R. B. Design, synthesis, and evaluation of novel ethambutol analogues. *Bioorg. Med. Chem. Lett.* 2008, 18, 1607–1611.
- (34) Noor, R.; Aidi, H.; Hafizi, F.; Khatib, S.; Zubair, A. F.; Rashid, H.; Parveen, B.; Akhtar, R. Facile synthesis, antibacterial and protease inhibition studies of β -amino alcohols prepared via ring opening of epoxides. *Pak. J. Pharm. Sci.* 2022, 35, 177–182.
- (35) de Souza Fernandes, F.; Fernandes, T. S.; da Silva, L. S.; Caneschi, W.; Lourenço, M. C. S.; Dias, C. G.; de Oliveira, P. F.; Martins, S. d. P. L.; Pereira, D. E.; Tavares, D. C.; Le Hyaric, M.; de Almeida, M. V.; Coari, M. R. C. Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols. *Eur. J. Med. Chem.* 2016, 108, 203–210.
- (36) Mishra, S.; Patel, S. Design, synthesis, and antibacterial activity of novel deoxycholic acid-amino alcohol conjugates. *Med. Chem.* 2020, 16, 385–391.
- (37) Liu, J.; Li, Y.; Ke, M.; Liu, M.; Zhan, P.; Xiao, Y.-C.; Chen, F. Unified strategy to amphiphilic antibiotics: asymmetric synthesis of (–)-chloramphenicol, (–)-andamphenicol, and (+)-thiamphenicol and its (+) 3-fluoride. *J. Org. Chem.* 2020, 85, 15360–15367.
- (38) Singh, N.; Rai, V. K.; Kumar, A. Aqueous mortar-pestle grinding: An efficient, attractive, and viable technique for the regioselective synthesis of β -amino alcohols. *C. R. Chim.* 2018, 21, 71–79.
- (39) Singh, N.; Das, A. A.; Kumar, A. A simple and efficient approach for the synthesis of 1, 3-oxazolidines from β -amino alcohols using grinding technique. *ChemistrySelect* 2018, 3, 13675–13681.
- (40) Fu, J.; Yang, Y.; Zhang, X.-W.; Mao, W.-J.; Zhang, Z.-M.; Zhu, H.-L. Discovery of 1H-benzotriazole-1-yl 1, 2, 3-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase. *Bioorg. Med. Chem.* 2010, 18, 8457–8462.
- (41) Eldrup, A. B.; Felding, J.; Kehler, J.; Dahl, O. New solid-phase synthesis of oligodeoxythymidinephosphorothioates by a modified HOFFMANN method. *Tetrahedron Lett.* 1995, 36, 6127–6130.
- (42) Dabhadre, P. S.; Jain, N. P. Synthesis and evaluation of antifungal activity of benzotriazole derivatives. *Asian J. Biomed. Pharm. Sci.* 2013, 3, 29–34.
- (43) Boido, A.; Vazzana, L.; Mattioli, F.; Sparatore, F. Anti-inflammatory and antinociceptive activities of some benzotriazole alcohols. *Il Farmaco* 2003, 58, 33–44.
- (44) Augustynowicz-Kopeck, E.; Zwińska, Z.; Orszako, A.; Kaimierczak, Z. Synthesis and antimicrobial activity of selected nitrobenzoylated benzotriazoles. *Acta Polym. Pharm. Drug Res.* 2008, 65, 435–439.
- (45) Nietzke, E.; Braunschweig, E. Ueber die einwirkung von aldehyden auf orthonitrophenylhydrazin. *Ber. Dtsch. Chem. Ges.* 1894, 27, 3381–3384.
- (46) Morgan, G. T.; Glover, T. CCXIV. Ortho-chloronitrobenzotriazoles. Part IV. 2-chloro-3,4-dinitrobenzotriazole. *J. Chem. Soc. Trans.* 1921, 119, 1700–1706.
- (47) Müller, E.; Hoffmann, W. Über die Einwirkung von Hydrazin auf Nitro- und Chloronitroderivate des Benzols und Naphthalins. III. Abhandlung: Über die Einwirkung von Hydrazinhydrat auf 2,4,5-Trichloronitrobenzol. *J. für Praktische Chemie* 1925, 111, 293–306.
- (48) König, W.; Geiger, R. Eine neue methode zur synthese von peptiden: aktivierung der carboxylgruppe mit dicyclohexylcarbodiimid unter nutze von 1-hydroxy-benzotriazolen. *Chem. Ber.* 1970, 103, 788–798.
- (49) Ma, X.; Song, Q.; Yao, L.; Li, M.; Hou, X. Study on the process of synthesis of 1-hydroxybenzotriazole. *Chem. Rev.* 2010, 11, 58–60.
- (50) Fathulla, M. F.; Khattab, S. N. Spectrophotometric determination of pK_a's of 1-hydroxybenzotriazole and oxime derivatives in 95% acetonitrile-water. *J. Chem. Soc. Pakistan* 2011, 33, 324–332.
- (51) Wang, C. Electrophilic ring opening of small heterocycles. *Synthesis* 2017, 49, 5307–5319.
- (52) Saddique, F. A.; Zahoor, A. F.; Fair, S.; Naqvi, S. A. R.; Usman, M.; Ahmad, M. Recent trends in ring opening of epoxides by amines as nucleophiles. *Synth. Commun.* 2016, 46, 831–868.
- (53) Arier, N.; Sidd, M. R. Highly chemoselective addition of amines to epoxides in water. *Org. Lett.* 2005, 7, 3649–3651.
- (54) Chakraborti, A. K.; Rudrawar, S.; Kondakar, A. Lithium bromide, an inexpensive and efficient catalyst for opening of epoxide rings by amines at room temperature under solvent-free condition. *Eur. J. Org. Chem.* 2004, 2004, 3597–3600.
- (55) Jalil, M. A.; Masum, S. M. A straightforward one-pot synthesis of biologically important imidazolidyl alcohols via catalytic epoxide ring-opening reactions. *Tetrahedron Lett.* 2012, 53, 3049–3051.
- (56) Chawla, B.; Kapoor, R.; Singh, A. K.; Yadav, I. D. S.; Kapoor, R.; Singh, A. K.; Yadav, I. D. S. A one-pot regioselective synthetic route to vinyl sulfones from terminal epoxides in aqueous media. *Green Chem.* 2012, 14, 1308–1313.
- (57) Yadav, I.; Singh, A.; Chawla, B. Click reaction of epoxides with anthranic acids using neat grinding to access benzotriazines. *Synthesis* 2012, 44, 2353–2358.
- (58) Phillips, O. A.; Shural, L. H. Oxazolidinone antimicrobials: a patent review (2012–2015). *Expert Opin. Ther. Pat.* 2016, 26, 591–605.
- (59) Qadlouni, M. G.; Phillips, O. A.; Korshak, S. E. A novel oxazolidinone derivative PH192 demonstrates anticommutant activity in vivo in rats and mice. *Eur. J. Pharm. Sci.* 2019, 130, 21–26.
- (60) Phillips, O. A.; Udo, E. E.; Abdel-Hamid, M. E.; Varghese, R. Synthesis and antibacterial activities of *N*-substituted-glycyl 1H-1, 2, 3-triazolyl oxazolidinones. *Eur. J. Med. Chem.* 2013, 66, 246–257.
- (61) Phillips, O. A.; Sham, L. H.; D'Silva, R.; Udo, E. E.; Benue, L. Evaluation of the monamine oxazolidinone inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. *Eur. J. Pharm. Sci.* 2015, 71, 56–61.
- (62) Hedayat, O. M.; Mathew, P. M.; Mohamed, F. H.; Phillips, O. A.; Luqmani, Y. A. Antiproliferative activity of a series of 5-(1H-1, 2, 3-triazolyl) methyl- and 5-oxazolidinomethyl-oxazolidinone derivatives. *Mol. Med. Rep.* 2016, 13, 3311–3318.
- (63) Al-Tamrak, N.; Phillips, O. Antimycobacterial activities of *N*-substituted-glycyl 1H-1, 2, 3-triazolyl oxazolidinones and analytical

method development and validation for a representative compound. *Sci. Pharm.* **2017**, *85*, 34.

(64) Dhill, P. P.; Nair, P. S.; Pail, V. J.; Jain, S.; Arora, S. K.; Srida, N. Synthesis and antibacterial activity of novel (un)substituted benzotriazabicyclo[3.3.0]octanone derivatives. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3002–3005.

(65) Phillips, O. A.; D'Silva, R.; Balta, T. O.; Sharaf, L. H.; Udo, E. E.; Benou, L.; Walters, D. E. Synthesis and biological evaluation of novel 5-(hydrazonic acid) methyl oxazolidinone derivatives. *Eur. J. Med. Chem.* **2015**, *106*, 120–131.

(66) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, F. C.; Petrin, T. E. UCSF chimera: a visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612.

(67) Trutt, G.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461.

(68) Demington, R.; Keith, T.; Millam, J. *Gauss View Version-5*; Semichem Inc.; Shawnee Mission, 2009.

(69) Fukui, K. *Theory of Orientation and Stereoselection*; Springer-Verlag Berlin Heidelberg: New York, 1975; p 112.

(70) Rai, V. K.; Singh, N. $\text{CaCl}_2 \cdot 7\text{H}_2\text{O}/\text{NaI}$ -promoted direct synthesis of 1,3-benzoxazine-2-thione *N*-nucleosides under microwave irradiation. *Nucleosides, Nucleotides, Nucleic Acids* **2013**, *32*, 247–255.

(71) Kumar, S.; Sharma, P.; Kapoor, K. K.; Husaid, M. S. An efficient, catalyst and solvent-free, four-component, and one-pot synthesis of polyhydroquinolines on grinding. *Tetrahedron* **2008**, *64*, 536–542.

(72) Kumar, A.; Kumar, S.; Kapoor, K. K. Zinc-Mediated Reductive Cyclodimerization of α,β -Unsaturated Aryl Ketones Under Aqueous Conditions. *Aust. J. Chem.* **2007**, *60*, 621–623.

(73) Kapoor, K.; Kumar, S. Unprecedented Reaction between Ethyl α -Cyanoacrylate and *o*-Phenylenediamine: Development of an Efficient Method for the Transfer Hydrogenation of Electronically Depleted Olefins. *Synlett* **2007**, 2007, 2809–2814.

(74) Ali, F.; Akbar, S.; Sillanpaa, M.; Yomas, U.; Ashraf, A.; Perveen, M.; Kaur, R.; Ahmad, I.; Alrifman, A. A.; Ouladimane, M. Recyclable Cu-Ag bimetallic nanocatalyst for radical scavenging, dyes removal and antimicrobial applications. *Chemosphere* **2023**, *313*, 137321.

(75) Ashraf, V.; Kushiwaha, M.; Arora, D.; Mallabhotla, S.; Jaglan, S. Mutation, chemoprototyping, demultiplication, and isolation of natural products from *Penicillium oxalicum*. *ACS Omega* **2021**, *6*, 16266–16272.

(76) Ashraf, V.; Kushiwaha, M.; Mallabhotla, S.; Jaglan, S. Chemical mutagenesis and high throughput media optimization in *Tolypocladium inflatum* MTCC-3538 leads to enhanced production of cyclosporine A. *J. Biotech* **2022**, *12*, 158.

(77) Dar, A. A.; Songwan, P. I.; Singh, N.; Kumar, A. Method validation and simultaneous quantification of five triterpenoids from *Codonopsis ovata* by high performance thin layer chromatography. *J. Planar Chromatogr.—Mod. TLC* **2019**, *32*, 251–256.

(78) Dar, A. A.; Raina, A.; Kumar, A. Development, method validation and simultaneous quantification of eleven bioactive natural products from high altitude medicinal plant by high-performance liquid chromatography. *Biomol. Chromatogr.* **2012**, *36*, No. e5408.

(79) Dar, A. A.; Ashraf, V.; Singh, N.; Gashish, E. A.; Dar, S. A. Recent bioanalytical methods for the isolation of bioactive natural products from genus *Codonopsis*. *Phytochem. Anal.* **2023**, *34*, 491–506.